Chong Kun Dang Pharmaceutical Cash Flow Conversion Efficiency
Chong Kun Dang Pharmaceutical cash flow conversion efficiency. Based on the latest financial reports, Chong Kun Dang Pharmaceutical (185750) has a cash flow conversion efficiency ratio of 0.012x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩12.32 Billion ≈ $8.35 Million USD) by net assets (₩1.03 Trillion ≈ $697.19 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Chong Kun Dang Pharmaceutical (2016–2025)
Cash flow conversion efficiency of Chong Kun Dang Pharmaceutical from 2016 to 2025. This chart illustrates how Chong Kun Dang Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Chong Kun Dang Pharmaceutical stock price today for real-time trading data and today's change.
Chong Kun Dang Pharmaceutical Cash Flow Conversion Ratio Explained
Chong Kun Dang Pharmaceutical cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Chong Kun Dang Pharmaceutical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chong Kun Dang Pharmaceutical ranked by their cash flow conversion efficiency. Also see Chong Kun Dang Pharmaceutical market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PDS Limited
NSE:PDSL
|
0.319x |
|
Ur Energy Inc
NYSE MKT:URG
|
-0.166x |
|
Sinoma Energy Conservation Ltd
SHG:603126
|
-0.039x |
|
Shinsung Delta Tech Co.Ltd
KQ:065350
|
0.051x |
|
E&R Engineering
TWO:8027
|
0.062x |
|
Korla Pear
SHG:600506
|
0.136x |
|
Delixi Xinjiang Transp Co Ltd
SHG:603032
|
0.024x |
|
Nanjing Vishee Medical Technology Co Ltd
SHG:688580
|
0.025x |
Annual Cash Flow Conversion Efficiency for Chong Kun Dang Pharmaceutical (2016–2025)
The table below shows the annual cash flow conversion efficiency of Chong Kun Dang Pharmaceutical from 2016 to 2025. Review Chong Kun Dang Pharmaceutical (185750) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩1.01 Trillion ≈ $681.99 Million |
₩67.36 Billion ≈ $45.65 Million |
0.067x | -6.68% |
| 2024-12-31 | ₩896.38 Billion ≈ $607.46 Million |
₩64.29 Billion ≈ $43.57 Million |
0.072x | -81.61% |
| 2023-12-31 | ₩815.64 Billion ≈ $552.74 Million |
₩318.16 Billion ≈ $215.61 Million |
0.390x | +257.79% |
| 2022-12-31 | ₩621.29 Billion ≈ $421.04 Million |
₩67.73 Billion ≈ $45.90 Million |
0.109x | +378.04% |
| 2021-12-31 | ₩565.81 Billion ≈ $383.44 Million |
₩12.90 Billion ≈ $8.74 Million |
0.023x | -87.94% |
| 2020-12-31 | ₩551.59 Billion ≈ $373.81 Million |
₩104.32 Billion ≈ $70.70 Million |
0.189x | +16.22% |
| 2019-12-31 | ₩474.95 Billion ≈ $321.87 Million |
₩77.29 Billion ≈ $52.38 Million |
0.163x | +64.50% |
| 2018-12-31 | ₩430.90 Billion ≈ $292.01 Million |
₩42.63 Billion ≈ $28.89 Million |
0.099x | -51.15% |
| 2017-12-31 | ₩403.29 Billion ≈ $273.31 Million |
₩81.67 Billion ≈ $55.35 Million |
0.203x | +24.15% |
| 2016-12-31 | ₩354.25 Billion ≈ $240.07 Million |
₩57.79 Billion ≈ $39.16 Million |
0.163x | -- |
About Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical Corp. manufactures, markets, and sells medicines in South Korea and internationally. It offers prescription drugs for anti-hypertension, anti-hyperlipidaemia, and anti-diabetics, as well as immunosuppressants; over-the-counter medicines; and consumer health products, such as insecticides and hair dye products, as well as health supplements. The company was founded in… Read more